ClinicalTrials.Veeva

Menu

A Study of Select Drug Combinations in Adult Patients With Advanced/Metastatic BRAF V600 Colorectal Cancer

Novartis logo

Novartis

Status and phase

Terminated
Phase 1

Conditions

BRAF V600 Colorectal Cancer

Treatments

Drug: TNO155
Drug: LTT462
Biological: Spartalizumab
Biological: Tislelizumab
Drug: LXH254
Drug: Trametinib
Drug: Dabrafenib

Study type

Interventional

Funder types

Industry

Identifiers

NCT04294160
CADPT01C12101

Details and patient eligibility

About

A phase Ib, open-label platform study of select drug combinations chosen in order to characterize safety and tolerability of each treatment arm tested and to identify recommended doses and regimens for future studies.

Full description

This is a phase Ib, multi-center, open-label study with multiple treatment arms in adult patients with advanced or metastatic BRAF V600 (E, D, or K) in order to characterize safety and tolerability of each treatment arm tested and to identify recommended doses and regimens for future studies. The open platform design of this study is adaptive to allow removal of combination treatment arm(s) based on emerging data and facilitate introduction of new candidate combinations. The study is comprised of a dose escalation part and may be followed by a dose expansion part for any combination treatment arm.

Enrollment

122 patients

Sex

All

Ages

18+ years old

Volunteers

No Healthy Volunteers

Inclusion and exclusion criteria

Key Inclusion Criteria:

  • Patients must have a site of disease amenable to biopsy, and be a candidate for tumor biopsy according to the treating institution's guidelines. Patients must be willing to undergo a new tumor biopsy at baseline and during on study therapy. Exceptions may be considered after documented discussion with Novartis.
  • All patients must have a BRAF V600 mutation confirmed by local assessment.
  • Patients with unresectable advanced/metastatic BRAF V600 cancer of the colon or rectum with measurable disease as determined by RECIST v1.1
  • Patients must have documented disease progression following, or are intolerant to, 1 or 2 lines of chemotherapy for advanced/metastatic disease

Key Exclusion Criteria:

  • Has a known additional malignancy that is progressing or requires active treatment. Exceptions include basal cell carcinoma of the skin or squamous cell carcinoma of the skin that has undergone potentially curative therapy, or in-situ cervical cancer, or other tumors that will not affect life expectancy
  • Impairment of gastrointestinal function or gastrointestinal disease that may signficantly alter the absorption of study drugs
  • History of or current evidence/risk of retinal verin occlusion or serous retinopathy
  • History of or current interstitial lung disease or non-infectious pneumonitis
  • Patients with a known history of testing positive for HIV
  • Clinically significant cardiac disease at screening
  • Any medical condition that would, in the investigator's judgment, prevent the patient's participation in the clinical study due to safety concerns or compliance with clinical study procedures.
  • Pregnant or lactating women

Other protocol-defined inclusion/exclusion may apply.

Trial design

Primary purpose

Treatment

Allocation

Non-Randomized

Interventional model

Parallel Assignment

Masking

None (Open label)

122 participants in 7 patient groups

Dabrafenib + LTT462 backbone arm 1
Experimental group
Description:
dose escalation to determine maximum tolerated dose (MTD)/ Recommended dose (RD) in adult patients with advanced or metastatic BRAF V600 colorectal cancer
Treatment:
Drug: Dabrafenib
Drug: LTT462
Dabrafenib + LTT462 + trametinib triplet arm 1
Experimental group
Description:
dose escalation to determine maximum tolerated dose (MTD)/ Recommended dose (RD) in adult patients with advanced or metastatic BRAF V600 colorectal cancer
Treatment:
Drug: Dabrafenib
Drug: Trametinib
Drug: LTT462
Dabrafenib + LTT462 + LXH254 triplet arm 2
Experimental group
Description:
dose escalation to determine maximum tolerated dose (MTD)/ Recommended dose (RD) in adult patients with advanced or metastatic BRAF V600 colorectal cancer - Arm is closed for further enrollment.
Treatment:
Drug: Dabrafenib
Drug: LXH254
Drug: LTT462
Dabrafenib + LTT462 + TNO155 triplet arm 3
Experimental group
Description:
dose escalation to determine maximum tolerated dose (MTD)/ Recommended dose (RD) in adult patients with advanced or metastatic BRAF V600 colorectal cancer
Treatment:
Drug: Dabrafenib
Drug: TNO155
Drug: LTT462
Dabrafenib + LTT462 + spartalizumab triplet arm 4
Experimental group
Description:
dose escalation to determine maximum tolerated dose (MTD)/ Recommended dose (RD) in adult patients with advanced or metastatic BRAF V600 colorectal cancer - Arm is closed for further enrollment.
Treatment:
Drug: Dabrafenib
Biological: Spartalizumab
Drug: LTT462
Dabrafenib + trametinib + TNO155 triplet arm 5
Experimental group
Description:
dose escalation to determine maximum tolerated dose (MTD)/ Recommended dose (RD) in adult patients with advanced or metastatic BRAF V600 colorectal cancer
Treatment:
Drug: Dabrafenib
Drug: Trametinib
Drug: TNO155
Dabrafenib + LTT462 + Tislelizumab triplet arm 6
Experimental group
Description:
dose escalation to determine maximum tolerated dose (MTD)/ Recommended dose (RD) in adult patients with advanced or metastatic BRAF V600 colorectal cancer
Treatment:
Drug: Dabrafenib
Biological: Tislelizumab
Drug: LTT462

Trial contacts and locations

18

Loading...

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems